On Sept. 5, the FDA announced an import alert and green list for glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredient (API) manufacturers. The FDA included manufacturers on the green list ...

NEW DELHI: In a major move towards ensuring drug security, India's import dependence for raw material to manufacture essential medicines is likely to reduce by 25% by around 2024, a top official said.

India revised the policy condition governing import of Sulphadiazine active pharmaceutical ingredient (API) recently by imposing a minimum import price (MIP). The import of Sulphadiazine API having a ...

The Ministry of Chemicals and Fertilizers will soon announce a ₹5,000-crore research programme aimed at reducing India’s import dependency on Active Pharmaceutical Ingredients (API) and promoting ...

For its upgraded drugs PLI scheme, the department of pharmaceuticals has sought applications for manufacturing raw materials required to produce life-saving antibiotics, antifungal drugs, and ...